LYNPARZA + ZYTIGA
Therapy
A combination of olaparib (AstraZeneca/Merck) and abiraterone used in biomarker-defined prostate cancer.
Approvals
2
Indications
1
Biomarkers
2
Mapped tests
2
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and LYNPARZA + ZYTIGA. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where LYNPARZA + ZYTIGA is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Metastatic Castrate Resistant Prostate Cancer (mCRPC) Solid Tumor · Prostate | BRCA1
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for LYNPARZA + ZYTIGA.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering LYNPARZA + ZYTIGA for eligible patients.
Test
FoundationOne CDx
Foundation Medicine, Inc.
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →
Test
FoundationOne Liquid CDx
Foundation Medicine, Inc.
Method
NGS
Specimen
Whole blood
1 approvalView test profile →